Nalaganje...

A robust prognostic gene expression signature for early stage lung adenocarcinoma

BACKGROUND: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a reliable prognostic biomarker for early stage patients would be critical to identify those most likely to benefit from early addition...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biomark Res
Main Authors: Krzystanek, Marcin, Moldvay, Judit, Szüts, David, Szallasi, Zoltan, Eklund, Aron Charles
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4761211/
https://ncbi.nlm.nih.gov/pubmed/26900477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-016-0058-3
Oznake: Označite
Brez oznak, prvi označite!